NCT03395392View on ClinicalTrials.gov

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

February 28, 2024

Study Completion Date

March 30, 2024

Conditions
Bipolar DepressionSuicidal Ideation and Behavior
Interventions
DRUG

NRX-101

NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth

DRUG

Lurasidone HCl

Lurasidone HCl will be given twice a day by mouth

Trial Locations (14)

14226

Dent Neurologic Institute, Amherst

20877

CBH Health, Gaithersburg

30030

iResearch Atlanta, LLC, Decatur

30331

ACMR, Atlanta

31405

iResearch Savannah, Savannah

33014

San Marcus Research Clinic, Inc., Miami Lakes

68144

Omaha Insomnia and Psychiatric Services, Omaha

76104

JPS Health, Fort Worth

77055

Houston Mind and Brain, Houston

77407

Health Texas, Richmond

78712

University of Texas Health Austin, Austin

78746

Roots Behavioral Health, Austin

90320

Science 37, Culver City

97401

Peace Health Medical Group, Eugene

Sponsors

Lead Sponsor

NeuroRx, Inc.
All Listed Sponsors
collaborator

Prevail Infoworks

INDUSTRY

lead

NeuroRx, Inc.

INDUSTRY

NCT03395392 - NRX-101 for Bipolar Depression With Subacute Suicidal Ideation | Biotech Hunter | Biotech Hunter